| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income (expense), net | 4,948 | 3,249 | ||
| Net loss | -20,148 | -25,335 | ||
| Net unrealized gains on marketable securities | 398 | -161 | ||
| Comprehensive loss | -19,750 | -25,496 | ||
| Net loss per share, basic | -0.32 | -0.49 | ||
| Net loss per share, diluted | -0.32 | -0.49 | ||
| Weighted average number of shares outstanding, basic | 62,093,795 | 52,105,052 | ||
| Weighted-average shares outstanding, diluted | 62,093,795 | 52,105,052 | ||
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)